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Abstract The incidence of breast and gynecological
cancers continues to increase in low and middle resource
countries [LRC’S and MRC’s] with a disproportionately
higher mortality rate compared to that in high resource
countries. This has been attributed to factors such as an
increased life span due to better control of communicable
diseases and improved nutrition, as well as lifestyle and
reproductive changes. A lack of public awareness and
understanding of these cancers, absence of an organized
screening program and a lack of accessible and effective
treatment options, is responsible for the higher mortality
rate. A practical approach of a combined program of
integrating a well woman examination with screening for
breast and cervical cancer and diagnostic evaluation for
Ovarian and Endometrial cancer in symptomatic women is
proposed in this article which can serve as a model to be
studied for efficacy in low resource countries.
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Introduction
In a low resource country, health care manpower and
infrastructure available for prevention, early detection or
treatment of cancer, is limited or nonexistent. Low income
countries are those countries where the per capita gross
national income is $995 or less [1]. In such a setting due to
a combination of lack of health care infrastructure, limited
access to health care, as well as economic, social and
cultural barriers that prevent women from seeking timely
care, the cancer mortality is high [2, 3]. Competing
healthcare needs in these countries with limited resource
means lower priority for cancer control interventions. The
background data on common cancers afflicting women are
presented below.
Background – Breast Cancer
Breast cancer is now the most frequently diagnosed cancer
as well as the leading cause of mortality from cancer in
women worldwide. It accounts for 23% of the total cancer
cases and 14% of deaths resulting from cancer in females
[4]. About 1 million new cases of breast cancer are
reported annually with 375,000 deaths. It has been
estimated that of more than 1 million new cases of breast
cancer that will be diagnosed worldwide in 2009, low- and
middle-resource countries will be burdened with 50% of
breast cancer cases and 60% of breast cancer related
deaths [4]. In 2010 the annual incidence of new cases is
expected to be 1.5 million, and it is estimated that by 2020
70% of all breast cancer cases will be in low and middle
resource countries [5].
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Background – Cervical Cancer
Low resource countries account for 80% of the half a
million cases of cervical cancer occurring annually. About
233,000 deaths result from cervical cancers [5]. Population
based screening programs in place in the developed nations
have successfully controlled mortality from cervical cancer.
Eighty-five percent of the deaths from cervical cancer occur
in low resource countries where screening programs are not
in place [5]. Current estimates of cervical cancer in these
countries may be an underestimate due to lack of reliable
cancer registries.
Background – Ovarian Cancer
The worldwide incidence of ovarian cancer according to the
GLOBOCAN database was 204,499 cases in 2002. Ovarian
cancer has a very high case fatality rate that results from it
being often diagnosed at late stages of disease [5].
Ovarian cancer (204,000 cases and 125,000 deaths) is
the sixth most common cancer and the seventh cause of
death from cancer in women (4.0% of cases and 4.2%
deaths [5]. Ovarian cancer occurs almost equally in the
developing and developed regions of the world. The case
fatality ratio is generally greater than 50% and over 70% in
East Africa. The prognosis has remained poor with no
change in the overall mortality rate. Women are often
diagnosed in Stage III and IV which carry a five year
survival rate of 27 and 16% respectively [5].
Background – Endometrial Cancer
There are about 200,000 new cases of endometrial cancers
diagnosed each year with about 50,000 fatalities. The
incidence is comparable to ovarian cancer with a much
better survival rate due to diagnosis at an earlier stage [5].
The relationship between obesity, anovulation and endome-
trial cancer make prevention and early diagnosis reasonable
goals even in low resource settings
Integrated Screening Strategy
The nucleus of this strategy would be a community based,
combined program for early detection of breast, cervical,
ovarian and endometrial cancer in low resource countries
delivered through a free standing or a mobile Well Woman
Clinic. The goal of such a program would be to downstage
cancers and improve mortality rates. The core strategy
would include combining a well woman examination with
Screening of asymptomatic women for breast and cervical
cancer and diagnostic assessment of symptomatic
women for Ovarian and Endometrial cancer. The
methodology of such a program is outlined in greater
detail below.
Screening – Breast and Cervical Cancer
Breast cancer: In low resource countries the age distribu-
tion of breast cancer is generally lower than in high
resource countries, although this has been attributed to the
average lower age of women in the population rather than
due to a higher age specific incidence, it is still advisable to
start screening at an earlier age. The target population
should include women in the age group of 30–59 years.
The proposed methodology would include an annual
clinical breast examination [CBE] followed by diagnostic
breast sonographic evaluation in screen positive women.
Those women in whom a palpable solid mass is seen and
determined to be suspicious based on ultrasound morpho-
logic features, Fine needle aspiration biopsy (FNAB) is
performed under ultrasound guidance for optimal sampling.
The rationale of this suggested methodology is explained
below.
Clinical Breast Examination [CBE] has been studied as a
low cost alternative to mammographic surveillance to
reduce mortality by early detection of breast cancer. CBE
identifies about 60% of cancers that are detected by
mammography and a few that are not seen at mammogra-
phy. There has been no randomized clinical trial undertaken
to evaluate the efficacy of CBE in the early diagnosis of
breast cancer by comparing women who received CBE and
those who did not. An estimate based on all randomized
clinical trials reported sensitivity of CBE for detection of
breast cancer at 54% and specificity at 94%. Indirect
evidence of its value comes from the Canadian National
Breast Screening study, where women were divided into
two groups one that received screening with physician
performed CBE alone , and a second group that received
both CBE and screening mammography . There were
39,405 women enrolled in this clinical trial. These inves-
tigators found that in the two groups, breast cancer
mortality and nodal involvement was similar [6–9]. A cost
effectiveness analysis of screening mammography and
clinical breast examination in India reported that a single
CBE at age 50 lead to a 2% decrease in breast cancer
mortality rate and had an estimated cost effectiveness ratio
of Int.$793 per life year gained, a 16.3% mortality rate
reduction was possible with biennial CBE at a cost
effectiveness ratio of Int.$1341, CBE performed annually
from ages of 40–60 years was estimated to be as
effective as Screening mammography for reducing breast
cancer mortality at a fraction of the cost [10]. It is
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therefore a very cost effective way of a first step in
screening for breast cancer.
Following a screening clinical breast examination further
assessment of screen positive cases is most optimally
carried out by diagnostic sonography rather than by
diagnostic mammography for many reasons. Mammogra-
phy has limitations in the evaluation of the symptomatic
woman, particularly in those with dense breasts. A false
negative rate as high as 16.5% has been reported for
mammography in patients with a palpable breast abnormality
[11]. Mammographic abnormalities identified in a symptom-
atic woman usually require additional diagnostic ultrasound
work up and those with a suspicious palpable solid mass
seen on a mammogram and a sonogram, the latter is a better
modality for tissue sampling (Fig. 1a–c). Overall, diagnostic
Ultrasound is superior and a cost effective alternative to
diagnostic mammography for the assessment of the symp-
tomatic patient in a LRC. Ultrasound is safe, well tolerated
by women, relatively inexpensive modality that can be
readily used in the evaluation of a palpable lump in a woman
where a positive physical finding was detected during the
course of a screening CBE. Ultrasound has also the added
potential of being used to stage breast cancer. Furthermore
this modality can be used for diagnosis of ovarian and
endometrial cancers making it a very cost effective invest-
ment in a well woman clinic that is envisaged in this
discussion (Tables 1 and 2).
The recommendations for triple assessment of symp-
tomatic women at a breast clinic traditionally consisted
of physical assessment, diagnostic mammography and
fine needle aspiration cytology [FNAB] [12]. As stated
above, substituting diagnostic mammography with diag-
nostic ultrasound is particularly suitable in low resource
settings. There is data to support the fact that findings of
cytology have to be considered in combination with
imaging morphology and characterization of solid masses
to improve the PPV thereby allowing for optimal
management of symptomatic women with suspicious
findings at imaging and cytology. In a consecutive series
of 2334 women PPV cytology findings of atypical,
suspicious and malignant was 55, 95.9 and 99.4%.
However when a atypical finding at cytology is seen in
combination with a suspicious finding on imaging the
PPV improved to 83.3% and PPV for suspicious lesions
increased to 98.5–98.7% potentially allowing for manage-
ment decisions of open biopsy and or planning surgery.
Although Core needle biopsies have been reported to be
more accurate than FNAB, in a LRC the latter is a more
Fig. 1 Series of ultrasound images in women with positive findings
on clinical breast examination. a 49 Year old female with a palpable
abnormality at the 9’o clock position of the right breast, sonography
reveals normal breast tissue. b 37 year old female with a palpable
abnormality at the 2 0’ clock position of the left breast , sonography
reveals a solid mass with benign morphologic features, proven to be a
Fibroadenoma at biopsy. c 43 year old with a palpable abnormality at
the 3’ o clock position of the left breast, sonography reveals a solid
mass with malignant morphologic features, proven to be an invasive
ductal cancer at biopsy
Table 1 Advantages of breast ultrasound over mammography in the
early detection of breast cancer
1. Cost effective modality: Initial capital expenditure and operational
expenses are considerably lower than for mammography
2. Sonographic examination of the breast is better tolerated by women
due to lack of breast compression unlike in mammography
3. Optimal modality for imaging guidance to improve accuracy
of FNAB
4. Ultrasound can be used to stage breast cancers thus aiding
in treatment planning and management
5. Ultrasound can be used for diagnosis of other cancers in Women
such as ovarian and endometrial cancer
6. Telemedicine feasible
7. Portable equipment easy to transport and for use in mobile clinics
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cost effective and feasible alternative. FNAB has the
advantages of being a minimally invasive procedure well
tolerated with minimal complications and patient discom-
fort with rapid results. FNAB’S are usually performed
using a 21–25-gauge needle and a 10-mL syringe mounted
on an aspiration device [13–17].
Cervical Cancer
In developing economies screening for cervical cancer is
generally recommended to commence at the age of 30 years
of age, the maximum impact of screening has been shown
when women are screened in their thirties [18–20].
Commencing screening of women in their 30’s allows
for identifying cancers in the preclinical phase thereby
maximizing the benefits of screening [20]. The optimal
age group to be targeted for cervical cancer screening is
30–59 years. Data published recently from a cluster
randomized trial of 137,461 women studied in India
demonstrated that even a single round of testing with
HPV [Human Papilloma Virus] DNA testing demonstrated
significant reductions in the number of cases of advanced
cancer and mortality from cervical cancer [18]. This
clinical trial examined the efficacy of a single round of
screening using Visual Inspection with acetic acid [VIA],
cytology testing [PAP smear] and HPV DNA testing on
the incidence of cervical cancer and associated death rates
[18]. Based on this large clinical trial and other previous
studies HPV DNA testing has been recommended for
implementation as a method for cervical cancer screening
in low resource countries [19]. The cost effectiveness of
such a strategy has also been previously published. The
most effective strategy — in terms of lives saved — was
use of a single lifetime HPV test, followed by Cryotherapy
for women who tested positive. Such an approach
demonstrated that the cost per year of life saved was $14
and the reduction of cervical cancer incidence was 32%
[20]. Although a single life time testing shows significant
reduction in mortality, more frequent testing adds to the
benefit of screening. Testing for HPVevery three years has
been shown to be very cost effective in saving lives [21].
HPV DNA testing can be undertaken in a two step
processes where during the initial clinic visit the test is
administered and test positive women are recalled for
Colposcopy. At Colposcopy women with abnormal findings
undergo biopsy followed by treatment by means of
Cryotherapy or LEEP [Loop electrosurgical Excisional
procedure] depending on the size of the abnormality.
Alternatively, use of single visit strategy may be adopted
which may be more beneficial in terms of cost savings and
ensuring better patient compliance and minimizing the risk
of loss to follow up. Single visit strategies is made possible
by using HPV testing of self collected samples or using
rapid processing of clinician collected sample. A simple,
affordable, and accurate HPV test [CareHPV test, Qiagen]
provides results within 3 h and was recently evaluated in
China; in this study the accuracy was found to be similar to
that of the Hybrid capture 11 test, with a higher sensitivity
than VIA. In the near future this test kit should be available
to be used in low resource countries. These two studies
clearly demonstrate the appropriateness of using HPV
testing as a primary screening method in low resource
countries [22].
Diagnostic Assessment – Ovarian and Endometrial
Cancer
Unlike Breast and Cervical cancer screening, benefits of
screening for ovarian and endometrial cancers have not
been shown, and is not appropriate in countries with limited
resources. However there may be a potential to detect these
cancers at an earlier stage by selectively examining post
menopausal women with symptoms suggestive of ovarian
and or endometrial cancer as part of a well woman
examination. We recognize that the yield may still be low
given the relatively low prevalence of these cancers;
however one has to keep in mind that performing these
additional evaluations suggested below, adds very little cost
to the envisaged program and may have the potential to
reduce the high mortality from being diagnosed at advanced
stages of ovarian and endometrial cancers.
Ovarian Cancer
It has been shown in several retrospective studies that
majority of women with ovarian cancer are symptomatic
even though some of these may be non gynecologic in
nature [23]. Goff and others have studied the value of using
a symptom index to help in the early diagnosis of ovarian
cancer. Women with ovarian cancer experienced symptoms
Table 2 Limitations of mammography as a screening modality
in LRC’S
1. Expensive to set up, resource intensive modality
2. Poor sensitivity in women with dense breasts
3. Cannot be used to guide FNAB
4. Mammographic findings of breast masses and focal asymmetry
need additional sonographic evaluation
5. 10% or higher recall rate is to be expected for women undergoing
screening mammography requiring an additional clinic visit
6. Not suited for telemedicine reads
7. Minimally invasive biopsy procedures for mammographic findings
requires stereotactic biopsy equipment which are expensive and time
consuming
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more frequently, of higher severity and of more recent onset
than women with benign masses or in the control
population. A combination of bloating increased abdominal
size and urinary symptoms was found in 43% of those with
cancer compared to 8% of those presenting to primary care
clinics. The authors of this study concluded that women
with more frequent, more severe and recent onset symp-
toms warrant further diagnostic investigation because they
are more likely to be associated with both benign and
malignant ovarian masses [23]. Goff and others in another
study reported that symptoms that were associated with
ovarian cancer were pelvic abdominal pain, urinary
frequency/urgency, increased abdominal size and bloating
and difficulty eating/feeling full. These symptoms are
particularly significant if present for less than year and
present >12 days per month. A symptom index was
considered positive if any of the following symptoms
occurred >12 times per month and present for <1 year:
Pelvic/abdominal pain, increased abdominal size/bloating,
difficulty eating/feeling full. In the confirmatory sample the
index had a sensitivity of 56.7% sensitivity for early
disease. Specificity was 90% for women >50 years [24].
Based on these studies we propose using the Goff symptom
index to identify women who need additional diagnostic
evaluation. Women in the age group of 50 to 69 with
symptoms indicating increased risk for ovarian cancer are
subjected to a pelvic examination and Endovaginal sonog-
raphy. The value of sonography in the diagnosis of ovarian
cancer has also been extensively studied. These studies
evaluated the role of sonography in screening for ovarian
cancer in combination with CA-125 testing. Data from The
United Kingdom Collaborative Trial of Ovarian Cancer
Screening (UKCTOCS), a randomized controlled trial
designed to assess the effect of screening on mortality,
reported that screening strategies for ovarian cancer are
feasible. Data from the initial screen demonstrated that
sensitivities for both multimodality screening and Ultrasound
screening strategies are encouraging [24]. In another large
study, TVS screening, when it was performed annually, was
associated with a decrease in disease stage at detection and
with case-specific ovarian cancer mortality [25].
Despite these encouraging results, sonographic ovarian
cancer screening of asymptomatic post menopausal women
has its limitations. High prevalence of benign adnexal
abnormalities detected on ultrasound means increased
surgical interventions which can lead to increased morbidity
and additional cost to the cancer control program. We
therefore recommend the selective use of Endovaginal
ultrasound in symptomatic women rather than as a screening
modality (Fig. 2a, b) .This is particularly relevant in a low
Fig. 2 Endovaginal ultrasound images of the ovaries in post
menopausal women. a 50 year old woman with normal appearing
ovary. b 56 year old symptomatic woman, sonographic images
demonstrate morphologic features that are suggestive of a malignancy,
surgery confirmed Ovarian cystadenocarcinoma
Fig. 3 Endovaginal ultrasound images of the uterus in women with
post menopausal bleeding. a 56 year old woman, sonography
demonstrates a normal appearing endometrium of 3 mm thickness. b
51 year old woman, sonography demonstrates an abnormally thickened
endometrium, at biopsy endometrial cancer was confirmed
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resource setting cost effectiveness and minimizing false
positive cases is critical.
Endometrial Cancer
Ultrasound evaluation of the endometrial thickness is the
accepted method to assess endometrial abnormalities in
post menopausal women. About 10% of post meno-
pausal women with abnormal bleeding are diagnosed
with endometrial carcinoma. About 75–80% of women
with endometrial carcinoma will present with abnormal
post menopausal bleeding. In these patients performance
of transvaginal ultrasound for assessment of the endo-
metrium identifies an abnormality in most women with
endometrial cancer. A large clinical study reported that
96% of endometrial carcinomas will be detected in
symptomatic post menopausal women if additional
procedures are performed only in those with an
endometrial thickness of >4 mm [26–29]. A thin and
regular endometrial lining is very reliable for the exclu-
sion of endometrial carcinoma in a post menopausal
patient with abnormal bleeding [30]. We recommend use
transvaginal sonography on post menopausal women with
abnormal bleeding to identify those women who will need
endometrial biopsy (Fig. 3a, b). An abnormal endometrium
detected on sonography would trigger endometrial sampling
following sonographic assessment. Like with screening
methods for Breast and cervical cancer, diagnostic assess-
ment for early detection of Endometrial and ovarian cancer
can be accomplished during a single visit.
Conclusion
There has been a dramatic increase in the incidence of
breast and cervical cancer associated with a high mortality
rate due to late presentation and lack of effective treatment
options in low resource countries. There is an urgent need
to implement a cost effective early detection healthcare
intervention strategy combined with making available
accessible and affordable treatment options. A cost effective
approach of combining strategies to detect multiple cancers
during a single clinic visit as a part of a well woman
examination is recommended.
Such a strategy would involve screening for breast
cancer using Clinical breast examination, diagnostic breast
ultrasound of screen positive cases and fine needle biopsy
of all solid masses that are deemed to be suspicious on
sonographic evaluation. For Cervical cancer screening,
HPV DNA testing followed by Colposcopic diagnosis and
treatment of precancerous lesions using a screen and treat
approach is recommended. Endovaginal sonographic assess-
ment of the ovaries in symptomatic post menopausal women
is recommended to aid in the early detection of ovarian cancer.
Sonographic assessment of the endometrium in symptomatic
post menopausal women followed by endometrial sampling in
those with an abnormal endometrium would aim to detect
endometrial cancer at an early stage. Screening for cervical
and breast cancer and diagnostic evaluation for early detection
of ovarian and endometrial cancers during a single clinic visit
serves to optimize patient compliance. We recognize that
unlike breast and cervical cancer, screening benefits have not
been proven for endometrial and ovarian cancer. Proposed
addition of testing of symptomatic post menopausal women is
still worthwhile despite the relatively lower prevalence of
these cancers considering that these tests add little to the
overall cost of the program when performed in conjunction
with a well woman examination.
We hope that the strategy outlined here can serve as a
starting point in implementing an intervention aimed at
controlling the increasing mortality from Breast and
Gynecological cancers in low resource countries. The
efficacy of such a combined screening and diagnostic
approach will have to be prospectively studied in a large
population of women so as to demonstrate its feasibility
and cost effectiveness.
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